```html

Mucopolysaccharidosis (MPS) – A Comprehensive Guide

Overview

Mucopolysaccharidosis (MPS) is a group of rare, inherited lysosomal storage disorders caused by a deficiency of enzymes that break down complex sugars called glycosaminoglycans (GAGs), also known as mucopolysaccharides. When these enzymes are missing or non‑functional, GAGs accumulate inside cells, leading to progressive damage in many organ systems.

There are at least seven recognized types (MPS I, II, IIIA‑D, IV A‑B, VI, VII, and IX), each linked to a different enzyme defect. The clinical severity can range from attenuated (milder) to severe forms that manifest in early childhood.

Who it affects: MPS is autosomal recessive for most types (both parents must carry a mutated gene), except MPS II (Hunter syndrome), which is X‑linked recessive and primarily affects males.

Prevalence (estimated worldwide):

• Overall combined prevalence ≈ 1 in 25,000–30,000 live births.
• MPS I (Hurler, Scheie, Hurler‑Scheie): ~1 in 100,000.
• MPS II: ~1 in 100,000–150,000 live male births.
• MPS III (Sanfilippo): ~1 in 70,000.
• MPS IV (Morquio): ~1 in 300,000.
• MPS VI (Maroteaux‑Lamy): ~1 in 250,000.
• MPS VII (Sly): <1 in 500,000 (very rare).

These numbers vary by region and ethnicity; some populations (e.g., certain communities in the Middle East) have higher carrier frequencies due to consanguinity.

Symptoms

Because GAGs build up in multiple tissues, MPS produces a broad spectrum of signs. Symptoms may appear in infancy, early childhood, or later, depending on the type and severity.

Common (cross‑type) features

• Coarse facial features – thickened lips, flattened nasal bridge, enlarged tongue.
• Growth retardation – short stature, delayed skeletal maturation.
• Joint stiffness or contractures – limited range of motion, especially in the hips, shoulders, and hands.
• Hernias – inguinal or umbilical, due to weakened connective tissue.
• Organomegaly – enlarged liver (hepatomegaly) and spleen (splenomegaly).
• Cardiac involvement – valve thickening (especially mitral and aortic), cardiomyopathy, arrhythmias.
• Respiratory problems – obstructive sleep apnea, recurrent infections, reduced lung capacity.
• Eye abnormalities – corneal clouding, glaucoma, retinal degeneration.
• Hearing loss – conductive, sensorineural, or mixed.
• Neurological decline (type‑specific) – developmental delay, cognitive impairment, seizures.

Type‑specific hallmark symptoms

Type	Key Enzyme Deficiency	Distinctive Features
MPS I (Hurler‑Scheie)	α‑L‑Iduronidase	Severe: developmental regression, airway obstruction, corneal clouding. Attenuated: milder skeletal disease, later onset.
MPS II (Hunter)	Iduronate‑2‑sulfatase	Often no corneal clouding; prominent organomegaly and behavioral issues.
MPS III (Sanfilippo) A‑D	Various heparan‑N‑sulfatases	Predominantly neuro‑cognitive decline; mild somatic signs.
MPS IV (Morquio) A‑B	GALNS (A) or GLB1 (B)	Severe skeletal dysplasia (short trunk, pectus carinatum); normal intelligence.
MPS VI (Maroteaux‑Lamy)	Arylsulfatase B	Severe cardiac and respiratory involvement; no primary CNS disease.
MPS VII (Sly)	β‑Glucuronidase	Variable; can include hydrops fetalis, severe organ involvement.
MPS IX (Natowicz)	Hylauronidase 2	Extremely rare; predominantly skeletal and joint disease.

Causes and Risk Factors

MPS results from mutations in genes that encode lysosomal enzymes. When the enzyme is missing or defective, GAGs cannot be broken down, leading to cellular accumulation.

Genetic inheritance patterns

• Autosomal recessive (MPS I, III, IV, VI, VII, IX): Both parents are carriers; each pregnancy has a 25 % chance of an affected child.
• X‑linked recessive (MPS II): Males are affected; carrier females have a 50 % chance of passing the mutated gene to sons.

Risk factors

• Consanguineous marriage (higher likelihood of both parents carrying the same recessive mutation).
• Family history of an MPS subtype.
• Certain ethnic groups have founder mutations (e.g., MPS I in the Dutch, MPS VI in some Brazilian communities).

There are no lifestyle or environmental factors that cause MPS; it is purely genetic.

Diagnosis

Early recognition is crucial. Diagnosis combines clinical suspicion with laboratory and imaging studies.

Screening & Initial Tests

• Urine glycosaminoglycan (GAG) analysis – Elevated dermatan, heparan, or keratan sulfate suggests MPS.
• Enzyme activity assay – Measured in leukocytes, fibroblasts, or dried blood spots; low activity confirms the specific type.

Confirmatory Genetic Testing

Sequencing of the implicated gene (e.g., IDS for MPS II) identifies pathogenic variants, guides prognosis, and enables carrier testing and prenatal diagnosis.

Imaging & Ancillary Studies

• Radiographs – “Dysostosis multiplex”: thickened calvarium, J‑shaped vertebrae, short ribs, and enlarged epiphyses.
• Echocardiography – Evaluates valve thickening and ventricular function.
• Pulmonary function tests (PFTs) – Detect restrictive lung disease.
• Ophthalmologic exam – Checks for corneal clouding, glaucoma, retinal changes.
• Audiometry – Assesses hearing loss.

Newborn Screening

As of 2024, several U.S. states and European programs include MPS I (and increasingly MPS II) in their dried‑blood‑spot panels, allowing treatment to begin before symptoms appear.

Treatment Options

Treatment aims to reduce GAG accumulation, manage complications, and improve quality of life. A multidisciplinary team (geneticist, metabolic specialist, cardiologist, orthopedic surgeon, ENT, physiotherapist, etc.) is essential.

Enzyme Replacement Therapy (ERT)

• MPS I – Laronidase (Aldurazyme®).
• MPS II – Idursulfase (Elaprase®).
• MPS VI – Galsulfase (Naglazyme®).
• MPS VII – Vestronidase alfa (Mepsevii®).

ERT is administered intravenously every 1–2 weeks. It improves organ size, lung function, and endurance but does not cross the blood‑brain barrier, so neurologic disease may continue.

Hematopoietic Stem Cell Transplant (HSCT)

Primarily used for severe MPS I (Hurler syndrome) in infants < 2 years old. Donor‑derived cells produce the missing enzyme, potentially preventing neuro‑cognitive decline. Risks include graft‑vs‑host disease and transplant‑related mortality (≈10‑15 %).

Substrate Reduction Therapy (SRT) & Gene Therapy (investational)

Small‑molecule approaches (e.g., odiparcil for MPS VI) aim to lower GAG synthesis. Early‑phase gene‑therapy trials (AAV‑mediated delivery) show promise, especially for CNS disease, but are not yet standard of care.

Symptomatic & Supportive Care

• Cardiac surgery – Valve replacement or repair as needed.
• Airway management – Adenotonsillectomy, CPAP/BiPAP for sleep apnea.
• Orthopedic interventions – Spinal fusion for cervical instability, corrective osteotomies, joint replacement.
• Physical & occupational therapy – Preserve range of motion, strengthen muscles.
• Hearing aids & cochlear implants – Treat conductive and sensorineural loss.
• Vision care – Corneal transplantation, glaucoma treatment.
• Pain management – NSAIDs, neuropathic agents, or procedural pain control.

Living with Mucopolysaccharidosis

While there is no cure for most forms, many patients lead productive lives with appropriate care.

Daily Management Tips

• Adherence to ERT schedule – Set reminders; arrange home infusion if possible.
• Routine monitoring – Cardiac echo every 6–12 months, pulmonary function tests annually, annual ophthalmology and audiology exams.
• Exercise – Low‑impact activities (swimming, cycling) maintain cardiovascular health without stressing joints.
• Joint protection – Use assistive devices (canes, custom orthotics) to reduce contractures.
• Nutrition – Balanced diet; consider high‑calorie supplements if growth falters.
• Psychosocial support – Counseling, support groups (e.g., National MPS Society), and school accommodations.
• Vaccinations – Keep up to date; avoid live vaccines during periods of immunosuppression after HSCT.

Family Planning & Genetic Counseling

Parents of an affected child should receive carrier testing and discuss prenatal options (chorionic villus sampling, amniocentesis) or pre‑implantation genetic diagnosis (PGD) for future pregnancies.

Prevention

Because MPS is inherited, primary prevention focuses on genetic counseling and carrier screening:

• Couples with a known family history should undergo targeted carrier testing.
• Population‑based carrier screening programs are emerging for MPS I and MPS II in certain countries.
• Pre‑implantation genetic diagnosis (PGD) enables selection of embryos without the pathogenic variant.

No lifestyle changes can prevent the disease once the genetic mutation is present.

Complications

If left untreated or inadequately managed, MPS can lead to serious, life‑limiting complications:

• Cardiac failure – Valve disease and cardiomyopathy.
• Respiratory insufficiency – Obstructive sleep apnea, bronchopulmonary infections, restrictive lung disease.
• Spinal cord compression – Cervical instability or kyphosis may cause neurologic deficits.
• Progressive skeletal deformities – Limiting ambulation, causing chronic pain.
• Hearing and vision loss – May lead to social isolation and academic difficulties.
• Neurological decline (primarily MPS I severe, MPS III, and some MPS II cases) – Cognitive regression, seizures, dementia.
• Renal failure – Rare, due to chronic GAG deposition.
• Reduced life expectancy – Historically 10–20 years for severe Hurler syndrome; with modern ERT/HSCT, many achieve adulthood.

When to Seek Emergency Care

References

• Mayo Clinic. Mucopolysaccharidosis (MPS) Overview. 2023. Link.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Lysosomal Storage Diseases. 2022.
• Cleveland Clinic. Enzyme Replacement Therapy for MPS. 2024.
• World Health Organization. WHO Guidelines for Rare Diseases. 2023.
• National MPS Society. Clinical Resources and Support. Updated 2024.
• GeneReviews. Mucopolysaccharidosis Type I (Hurler, Scheie, Hurler‑Scheie). 2023.
• American Academy of Pediatrics. Newborn Screening for Lysosomal Disorders. 2024.

```